Login to Your Account

Gilead Sets the Bar at 100% for Interferon-Free HCV Regimen

By Catherine Shaffer
Staff Writer

Monday, November 12, 2012

Gilead Sciences Inc. reported stunning interim results from its Phase II ELECTRON study of 12 weeks of therapy with investigational hepatitis C (HCV) combo sofosbuvir (GS-7977) and GS-5885 with ribavirin showing the best-possible results at four weeks after treatment, a 100 percent sustained virologic response (SVR4).

The trial enrolled 25 patients with genotype 1 chronic HCV, as is considered predictive of cure rates at 12 weeks after treatment (SVR12).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription